

RespireRx Pharmaceuticals Inc.  
Form 8-K/A  
July 18, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**(Amendment No. 1)**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 11, 2017**

**RESPIRERX PHARMACEUTICALS INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>1-16467</b>	<b>33-0303583</b>
<b>(State or other jurisdiction of incorporation)</b>	<b>(Commission File Number)</b>	<b>(I.R.S Employer Identification No.)</b>

**126 Valley Road, Suite C**

**07452**

**Glen Rock, New Jersey**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (201) 444-4947**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## **Explanatory Note**

This Amendment No. 1 amends the Current Report on Form 8-K filed by RespireRx Pharmaceuticals Inc. (the “Company”) on July 11, 2017 (the “Original Form 8-K”) solely to correct the Ampakine Executive Summary furnished as Exhibit 99.3 thereto (the “Exhibit”). As previously furnished, the Exhibit inadvertently did not include certain attribution information for some of the material presented therein; this has been corrected in the version of the Exhibit furnished with this Amendment No. 1. No other changes have been made to the Original Form 8-K.

## **Item 7.01 Regulation FD Disclosure**

Exhibit 99.3 attached hereto replaces Exhibits 99.3 furnished on the Original Form 8-K. The foregoing information is furnished pursuant to Item 7.01 Regulation FD Disclosure and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

## **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

A list of exhibits that are furnished as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 17, 2017 RESPIRERX PHARMACEUTICALS INC.

By: */s/ Jeff E. Margolis*  
Jeff E. Margolis

Senior Vice President, CFO, Treasurer and Secretary

**EXHIBIT INDEX**

**Exhibit Number Exhibit Description**

99.3 Ampakine Executive Summary\*

\* Furnished herewith.

